Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nanopartículas multicomponente para transfección y selección celular

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190226003
Publicado:
07/03/2019
Caducidad:
07/03/2020
Resumen:
Un centro de investigación español que reúne algunos de los principales grupos de investigación españoles en biomedicina de más de 100 instituciones (universidades, hospitales y centros tecnológicos) ha desarrollado nuevas nanopartículas de administración de genes para transfección y selección celular. La terapia génica ha surgido como una técnica pionera para tratar o mejorar la salud modificando las células del paciente genéticamente (utilización directa de ácidos nucleicos como medicamento). Las nuevas nanopartículas mejoran la eficiencia de transfección celular, promueven la endocitosis de partículas para la administración del polinucleótido objetivo y facilitan la separación rápida y masiva de las células que contienen partículas aplicando un fuerte campo magnético. El centro de investigación busca compañías biotecnológicas y farmacéuticas con el fin de establecer acuerdos de licencia, investigación o cooperación técnica.

Details

Tittle:
Multicomponent nanoparticles for cell transfection and selection
Summary:
A Spanish research centre has developed innovative non-viral gene delivery nanoparticles for cell transfection and selection. They seek license, research cooperation or technical cooperation agreements with Biotech and Pharma companies.
Description:
This research networking center gathers some of the main Spanish research groups in biomedicine, located in more than 100 institutions as universities, hospitals and technological centers distributed around the country.
Gene therapy has arisen as a pioneering technique to treat or improve the health condition of the patient by modifying the patient´s cells genetically (direct employment of nucleic acids as medicine).
The major historical problem is to develop efficient and safe systems for the delivery of therapeutic genes (modified DNA) into the target cells. The delivery of modified DNA into cells (transfection) can be accomplished by multiple methods (vectors). The present vectors used for gene therapy are broadly classified as Viral vectors (recombinant, biological nanoparticles), Non-viral vectors and engineered vectors (Naked DNA, inorganic nanoparticles, dendrimers, oligonucleotides). The efficiency of transfecting host cells is relatively high with viral vectors compared to non-viral methods, however, the major advantage of using non-viral vectors is its bio-safety. Non-viral vectors have drawn significant attention due to its less immunotoxicity. Use of non-viral vectors in clinical trials has increased in the last years while that of viral vector saw significant decrease. Advances in efficiency, specificity, gene expression duration and safety led to an increased number of non-viral vector products entering clinical trials.
Unfortunately, none of the currently available non-viral vectors fulfills ideal vector properties. This has led to research focus on suitable ideal vector delivery system.
They are looking to establish license, research cooperation or technical cooperation agreements.
Advantages and Innovations:
The new nanoparticles enhance cell transfection efficiency, promotes particle endocytosis for delivery of the target polynucleotide and facilitate rapid and massive separation of particle-containing cells by application of a strong magnetic field.
The new multicomponent particles enhance the transfection efficiency on different cell types.
The specific components of the nanoparticle are: a superparamagnetic metallic oxide, certain poly(beta-amino ester)s and a polynucleotide.
These nanoparticles allow the rapid and massive separation of particle-containing cells by application of a strong magnetic field.
It can also be used as a magnetic resonance contrast for magnetic resonance imaging and tracking of labelled cells, when said cells are used for clinical or live animal research.

Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority European patent application filed
Suitable for international extension (PCT)

Partner sought

Type and Role of Partner Sought:
Patent ready for licensing-out via license agreements.

The research center is seeking industrial partners, either Biotech or Pharma, to:
- enter into preclinical R-Y-D collaboration (in vitro and/or in vivo drug testing)
- Further development until clinical proof-of-concept

Besides, the research center is looking for R-Y-D institutions to establish tecnhical cooperation agreements or research cooperation agreements.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001009 Terapia genética - ADN
06001018 Virus, virología / antibióticos / bacteriología